---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052110"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:48:48.654838+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q1 net loss $81.4M; cash $749.6M, Genentech milestone boosts revenue

## Summary
- Net loss $81.4M ($0.62/share) vs $94.2M ($0.78/share) in Q1 2023; loss narrowed.
- Revenue $10.0M vs $0.2M YoY, driven by $10M milestone from Genentech collaboration.
- Cash and investments $749.6M, expected to fund operations into H2 2026.
- R&D expenses $82.4M, relatively flat vs $82.8M year ago.
- RLY-2608 doublet and triplet trials enrolling; lirafugratinib data and regulatory update expected H2 2024.

## SEC filing metadata
- accession: 0000950170-24-052110
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024052110/0000950170-24-052110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024052110/rlay-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052110
- JSON: https://secwatch.observer/filing/0000950170-24-052110.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052110.txt

## Key facts
- Earnings Releases
  Relay Therapeutics, Inc. reported first quarter 2024 results: revenue $10.0 million, net income $81.4 million, EPS $0.62.
  - Period: first quarter 2024
  - Revenue: $10.0 million
  - Net income: $81.4 million
  - EPS: $0.62
  - Result: reported results
  source text: The company expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026. Revenue: Revenue was $10.0 million for the first quarter of 2024, as compared to $0.2 million for the first quarter of 2023. The increase was primarily due to a payment of $10.0 million in connection with a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017024052110/0000950170-24-052110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.